Cullinan Therapeutics is a clinical-stage biopharmaceutical company developing therapies in oncology and immunology. Its pipeline centers on antibody and other targeted modalities designed for patients with serious cancers and immune-mediated diseases. As a development-stage company, it generates little product revenue and advances candidates through clinical trials rather than commercial-scale sales.
| Quarter | Revenue | YoY % | Earnings | YoY % |
|---|---|---|---|---|
| Q2 2025 | 0 | — | -70.1 | — |
| Q3 2025 | 0 | — | -50.6 | — |
| Q4 2025 | 0 | — | -50.7 | — |
| Q1 2026 | 0 | — | -49.7 | — |
| Q2 2026 | 0 | — | -53.7 | — |
All markets — KeepWinning global stock screener
Other companies on Nasdaq: Monte Rosa Therapeutics, Inc. (GLUE), Daily Journal Corporation (DJCO), Strategy Inc (STRD), Liberty Capital Corporation (GLIBK), Sify Technologies Limited (SIFY), Odyssey Therapeutics, Inc. (ODTX)